IlgANN 2025: Recent real-world research on Nufekang confirms the long-term effectiveness and safety of treatment in the treatment of certain conditions.

On September 18, at the 18th International IgA Nephropathy Conference (IIgANN 2025), NEFECON exhibited 7 latest real-world research data from multiple top hospitals in China. One important observational study evaluated the effectiveness and safety of NEFECON in treating IgA nephropathy for 12 months, confirming significant clinical benefits in the "long-term targeted therapy" of IgA nephropathy. This research not only provided clear direction for the follow-up treatment of IgA nephropathy patients after a 9-month course, but also provided valuable evidence-based medical support for the long-term treatment of lgA nephropathy patients. The 18th International IgA Nephropathy Conference was held in Prague, Czech Republic from September 17th to 20th. IgA nephropathy is a chronic autoimmune glomerular disease with a hidden onset. Currently, IgA nephropathy is more common in Asia, with an increased risk of progressing to end-stage kidney disease in Asian populations 56% higher than in other populations, and the disease progresses more rapidly. IgA nephropathy is also one of the main causes of kidney failure in young and middle-aged Chinese adults, with approximately 60% of Chinese patients progressing to end-stage kidney disease (ESRD) within 15 years, causing multiple pressures on patients, families, and society. Therefore, it is crucial to delay disease progression and protect kidney function through long-term targeted therapy for IgA nephropathy. To further explore the value of continuing NEFECON treatment after completing a 9-month course, the retrospective study presented at IIgANN 2025 aimed to evaluate the real-world efficacy and safety of 12 months of budesonide enteric capsules treatment in patients with IgA nephropathy and compared it with traditional treatments. The study included 12 IgA nephropathy patients confirmed by biopsy who received 12 months of budesonide enteric capsules treatment (16 mg/d), as well as 36 propensity score-matched control group patients who received traditional treatment (mainly corticosteroids and immunosuppressive agents). The results showed that after 12 months, the 24-hour urine protein in the budesonide enteric capsules group decreased from 1016 mg to 114 mg (P=0.037), significantly lower than the control group's 291mg (P=0.01). The eGFR slope in the budesonide enteric capsules group was significantly better than the control group (5.4 ml/min/1.73m2/year vs. -3.4 ml/min/1.73m2/year, P=0.032), with no severe infections reported. The study indicated that 12 months of budesonide enteric capsules treatment significantly reduced proteinuria levels in IgA nephropathy patients, protected kidney function, and was safer than traditional treatment. Professor Lu Jicheng from Peking University First Hospital stated, "IgA nephropathy is the most common chronic glomerulonephritis worldwide, especially prevalent in Asian populations, with a 15-year kidney survival rate after diagnosis as low as 40%, making the disease burden heavy. The treatment of IgA nephropathy should follow the core goal of 'short-term proteinuria control, long-term kidney function stability.' The 2025 version of the 'Chinese Adults IgA Nephropathy and IgA Vasculitis Clinical Practice Guidelines (preliminary version)' clearly stated that patients should control proteinuria to <0.5 g/d (<0.3 g/d is better) in the short term, and after achieving the goal, a scheme including low-dose maintenance or repeat safe immunotherapy should be adopted to ensure that eGFR declines by <1 ml/min per year, fundamentally reducing the risk of kidney failure. This emphasizes the importance of immunotherapy in the long-term treatment of IgA nephropathy. Budesonide enteric capsules, as the only approved targeted therapy drug for IgA nephropathy, with its mucosal immunomodulatory effect on intestinal B cells, reducing pathogenic IgA production from the source, has been unanimously recommended by authoritative guidelines both domestically and internationally. The Chinese studies presented at IIgANN 2025 further confirm that 12 months of budesonide enteric capsules treatment can reduce patients' 24-hour urine protein from 1016 mg to 114 mg, significantly better than the traditional treatment group, and the change in eGFR is also significantly better than the control group, with no severe infections reported, and only a few patients experiencing mild side effects, demonstrating good tolerability. This study clarifies the direction of follow-up treatment for IgA nephropathy patients after a 9-month course, and lays the foundation for the value of budesonide enteric capsules in the long-term management of the disease." CEO Luo Yongqing of EVEREST MED (01952) stated, "The latest real-world research results of NEFECON presented at IIgANN 2025 have shown that extending treatment with NEFECON after completing a 9-month course can continue to benefit patients, with safety superior to traditional treatment options, confirming the clinical value of NEFECON in 'long-term targeted therapy.' This latest real-world research further solidifies NEFECON's cornerstone position as first-line therapy for IgA nephropathy and scientifically demonstrates the clinical value and necessity of making 'long-term targeted therapy' the core disease management strategy. It is estimated that there are over 5 million IgA nephropathy patients in China, with over 100,000 new diagnoses each year. Chinese IgA nephropathy patients progress rapidly with poor prognosis, indicating significant unmet clinical needs. As the world's first and currently the only targeted therapy drug for IgA nephropathy approved in China, the United States, and Europe, not limited by proteinuria levels, NEFECON is continuously reshaping the treatment pathway for IgA nephropathy, providing more effective treatment options for IgA nephropathy patients, and helping improve the long-term quality of life for patients. NEFECON is currently the world's first IgA nephropathy treatment drug to be fully approved by the China National Medical Products Administration (NMPA), the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, and other authorized regions in Asia (Hong Kong, Macau, Taiwan, Singapore, and Korea) by EVEREST MED.